Long Term Azithromycin in Cystic Fibrosis: Another Possible Mechanism of Action?

References

• Boucher RC. New concepts of the pathogenesis of cys-tic fibrosis lung disease. Eur Respir J 2004; 23 (1): 146–58.
   PubMed Web of Science ®Google Scholar
• Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229–1256.
   PubMed Web of Science ®Google Scholar
• Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531–532.
   PubMed Web of Science ®Google Scholar
• Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchioli-tis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829–1832.
   PubMed Web of Science ®Google Scholar
• Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a ran-domized trial. Thorax 2002; 57: 212–216.
   PubMed Web of Science ®Google Scholar
• Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long-term azithromycin in children with cystic fibrosis: a random-ized, placebo-controlled crossover trisl. Lancet 2002; 360: 978–984.
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infect-ed with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290 (13): 1749–1756.
   Google Scholar
• Jaffè A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
   PubMed Web of Science ®Google Scholar
• Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156 (1): 266–71.
   PubMed Web of Science ®Google Scholar
• Yamasawa H, Oshikawa K, Ohno S, Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol. 2004; 30 (4): 569–75.
   PubMed Web of Science ®Google Scholar
• Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461 (2): 237–262.
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–1654.
   PubMed Web of Science ®Google Scholar
• Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vivo induction of liver p-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995; 133: 269–276.
   PubMed Web of Science ®Google Scholar
• Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug-resistance p-glycoprotein. Nature 1992; 335: 830–833.
   Web of Science ®Google Scholar
• Hainsworth AH, Henderson RM, Hickman ME, et al. Hypotonicity-induced anion fluxes in cells expressing the mul-tidrug-resistance-associated protein (MRP). Eur J Physiol 1996; 432: 234–240.
   PubMed Web of Science ®Google Scholar
• Jirsch J, Deeley RC, Cole SP, Stewart AJ, Fedida D. Inwardly rectifying K+ channels and volume-regulated anion channels in multidrug-resistant small cell lung cancer cells. Cancer Res 1993; 53: 4156–4160.
   PubMed Web of Science ®Google Scholar
• Gibson LE, Cooke RE. A test for concentration of elec-trolytes in sweat in cystic fibrosis of the pancreas utilizing pylocarpine by iontophoresis. Pediatrics 1959; 23: 544–549.
   Google Scholar
• Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocol for assessing effi-cacy of gene transfer in cystic fibrosis. Human Gene Therapy 1995; 6: 445–455.
   PubMed Web of Science ®Google Scholar
• Pradal U, Castellani C, Delmarco A, Mastella G. Nasal potential difference in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 1998; 158: 896–901.
   PubMed Web of Science ®Google Scholar
• Mini E, Biondi C, Morganti M, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999; 11: 437–445.
   Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Annal Biochem 1987; 162: 156–159.
   PubMed Web of Science ®Google Scholar
• Narasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res 1996; 16: 2079–2082.
   PubMed Web of Science ®Google Scholar
• Horikoshi T, Danenberg KD, Stadlbauer THW, et al. Quantitation of thymidylate synthase, dihydrofolate reductase and DT-diaphorase gene expression in human tumors using polymerase chain reaction. Cancer Res 1992; 52: 108–116.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295–1302.
   PubMed Web of Science ®Google Scholar
• Giaccone G, van Ark-Otte J, Rubio CJ, et al. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs. Int J Cancer 1996; 66: 760–767.
   PubMed Web of Science ®Google Scholar
• Brechot JM, Hurbain I, Fajac A, Daty N, Berbaudin JF. Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem 1998; 46: 513–517.
   PubMed Web of Science ®Google Scholar
• Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8: 67–113.
   PubMedGoogle Scholar
• Linsdell P, Hanrahan JW. Substrates of multidrug resis-tance- associated proteins block the cystic fibrosis transmem-brane conductance regulator chloride channel. J Pharmacol 1999; 126: 1471–1477.
   Google Scholar
• Lallemand JY, Stoven V, Annereau JP, et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350: 711–712.
   PubMed Web of Science ®Google Scholar
• Altschuler EL. Azithromycin, the multidrug resistant protein, and cystic fibrosis. Lancet 1998; 351 (9111): 1286.
   PubMed Web of Science ®Google Scholar
• Rosenstein BJ, Cutting GR, Boat TF, et al. The diag-nosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132: 589–595.
   PubMed Web of Science ®Google Scholar
• Delmarco A, Pradal U, Cabrini G, Bonizzato A, Mastella G. Nasal potential difference in cystic fibrosis patients presenting borderline sweat test. Eur Respir J 1997; 10: 1145–1149.
   PubMed Web of Science ®Google Scholar
• Noone PG, Hohneker KW, Thou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000; 1: 105–114.
   PubMed Web of Science ®Google Scholar
• Alton EW, Stern M, Farley R, et al. Cationic lipid-medi-ated CFTR gene transfer to the lung and nose of patients with cystic fibrosis: a double blind placebo-controlled trial. Lancet 1999; 353: 947–954.
   PubMed Web of Science ®Google Scholar
• Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-depen-dent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996; 2271-2275.
   Google Scholar
• Jaffè A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31: 464–473.
   PubMed Web of Science ®Google Scholar